Optimizing treatments in rare diseases: will our evidence come from registry data?

Leuk Res. 2014 Apr;38(4):421-2. doi: 10.1016/j.leukres.2014.01.015. Epub 2014 Feb 6.

Author

Antonio M Almeida¹

Affiliation

¹ Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal. Electronic address: amalmeida@ipolisboa.min-saude.pt.

PMID: 24631371
DOI: 10.1016/j.leukres.2014.01.015

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antimetabolites, Antineoplastic / therapeutic use*
Azacitidine / therapeutic use*
Female
Humans
Leukemia, Myelomonocytic, Chronic / drug therapy*
Leukemia, Myelomonocytic, Chronic / mortality*
Male

Substances

Antimetabolites, Antineoplastic
Azacitidine